KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.91 $2.71 Friday, 26th Apr 2024 CANF stock ended at $1.98. This is 3.13% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 4.71% from a day low at $1.91 to a day high of $2.00.
90 days $1.91 $2.71
52 weeks $1.71 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Feb 16, 2022 $1.12 $1.19 $1.12 $1.16 102 277
Feb 15, 2022 $1.11 $1.15 $1.11 $1.14 79 315
Feb 14, 2022 $1.08 $1.12 $1.08 $1.12 83 906
Feb 11, 2022 $1.15 $1.16 $1.10 $1.10 178 445
Feb 10, 2022 $1.12 $1.18 $1.11 $1.16 173 291
Feb 09, 2022 $1.11 $1.14 $1.10 $1.13 304 689
Feb 08, 2022 $1.11 $1.13 $1.09 $1.09 170 663
Feb 07, 2022 $1.10 $1.14 $1.10 $1.13 234 880
Feb 04, 2022 $1.12 $1.13 $1.07 $1.13 241 430
Feb 03, 2022 $1.10 $1.11 $1.07 $1.10 193 400
Feb 02, 2022 $1.16 $1.20 $1.11 $1.12 477 417
Feb 01, 2022 $1.15 $1.19 $1.15 $1.18 329 613
Jan 31, 2022 $1.13 $1.17 $1.12 $1.17 472 504
Jan 28, 2022 $1.08 $1.15 $1.06 $1.15 378 383
Jan 27, 2022 $1.13 $1.15 $1.05 $1.06 406 846
Jan 26, 2022 $1.20 $1.20 $1.11 $1.13 416 127
Jan 25, 2022 $1.14 $1.17 $1.13 $1.17 232 856
Jan 24, 2022 $1.19 $1.20 $1.07 $1.14 848 978
Jan 21, 2022 $1.26 $1.28 $1.20 $1.21 666 081
Jan 20, 2022 $1.29 $1.36 $1.26 $1.29 334 512
Jan 19, 2022 $1.28 $1.36 $1.25 $1.29 761 126
Jan 18, 2022 $1.31 $1.31 $1.22 $1.23 507 474
Jan 14, 2022 $1.29 $1.31 $1.26 $1.31 676 752
Jan 13, 2022 $1.33 $1.35 $1.30 $1.31 538 782
Jan 12, 2022 $1.35 $1.35 $1.26 $1.34 645 126
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT